10.1177/1056789514562152

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Previous studies have reported an increased risk of new cardiovascular events and differences in treatment after acute coronary syndrome (ACS) in people with HIV (PWH) compared with people without HIV (PWOH). Our aim was to compare the contemporary in-hospital treatment, lipid-lowering therapy and 1-year outcomes after ACS in PWH and PWOH in Finland. We collected data retrospectively from national registers and matched each PWH with ACS in 2017-2023 to PWOH 1:4 by age, sex, year, and area. The study included 35 PWH and 128 PWOH. Of them, 30 PWH (86%) and 119 PWOH (93%) underwent coronary angiography with no difference in invasive treatment after angiography [22/28 PWH (79%) and 79/103 PWOH (77%); those with zero occluded arteries excluded]. One-year mortality was comparable. PWH had more new cardiovascular events during follow-up [5 PWH (15%) vs. 13 PWOH (10%)] driven by elective revascularizations and recurrent ACS, but with no statistical evidence of a difference [HR 1.42 (95% CI: 0.50-3.98)]. Lipid-lowering therapy was prescribed to 18/19 PWH (95%) and 74/79 PWOH (94%), with >80% of the medication high-intensity for both PWH and PWOH. All but two people purchased the medication after discharge, and 92% of the whole population at 6 to 12 months after the ACS. Still, only 37% of PWH and 30% of PWOH achieved low-density lipoprotein (LDL) values <1.4 mmol/L by 1 year. In conclusion, there were no major differences by HIV status in the treatment and outcomes of ACS in 1-year follow-up, but the results indicate that secondary prevention should be enhanced.

Abstract: PubMed · Datensatz